Brian L. Wilson
Brian L. Wilson
Stop FollowingBrian L. Wilson
View as an RSS Feed
View Brian L. Wilson's Articles BY TICKER:
AAPL,
ABIO,
ABT,
ACAD,
ACHN,
ACRX,
AEGR,
AEZS,
AFFY,
ALXA,
AMPE,
AMRN,
AMZN,
ANAC,
ANTH,
APPA.OB,
APPY,
ARAY,
ARIA,
ARNA,
ARQL,
ARRY,
ASTX,
ATHX,
ATRS,
AVEO,
BAC,
BBRY,
BCRX,
BHP,
BIIB,
BLRX,
BMRN,
C,
CBMX,
CELG,
CHTP,
CLDX,
CLSN,
CORT,
CPRX,
CRME,
CUR,
CVM,
CYCC,
CYNO,
CYTK,
DARA,
DCTH,
DIS,
DMPI.OB,
DNDN,
DSCO,
DVAX,
EDAP,
EXEL,
F,
FOLD,
FRX,
FURX,
GALT,
GE,
GSK,
GWAY,
HALO,
HPTX,
HZNP,
IBM,
IMGN,
INO,
INTC,
ISIS,
ITMN,
JNJ,
JPM,
KERX,
KO,
LLY,
LNG,
LON,
LPTN,
LXRX,
MAKO,
MDVN,
MNKD,
MRK,
MSLP.OB,
MYRX,
NAVB,
NPSP,
NSPH,
NVS,
OMER,
ONCY,
ONXX,
OPXA,
ORCL,
OREX,
OSIR,
OSUR,
OXY,
PCRX,
PCYC,
PFE,
PGNX,
PPHM,
PTN,
QCOR,
REGN,
RIGL,
RMTI,
RPRX,
RPTP,
SCMP,
SDRL,
SGMO,
SKUL,
SLV,
SNGX.OB,
SPPI,
SPY,
SRPT,
STML,
STXS,
SUPN,
T,
THRX,
TKMR,
TLON.OB,
TTNP.OB,
VRTX,
VVUS,
WMT,
ZGNX,
ZIOP
- Anthera Shifts Its Strategy For Blisibimod
- Cytokinetics' New Rally Pauses On Buyer Exhaustion
- BioCryst Makes A Small Recovery Following Last Year's Bad News
- A.P. Pharma Anticipates FDA Decision On APF530
- Investing In The Future Of Multiple Myeloma Treatment
- Dendreon Jumps On Provenge's Turnaround
- Isis Heats Up Ahead Of FDA Decision On Kynamro
- Antares Rallies Quickly And Confidently On Newest Developments
- Novartis Improves Its Oncology Pipeline With Cutting Edge Technology
- 2013 Will Be A Telling Year For Discovery Laboratories
- Pfizer Takes Interest In Halozyme's Biologics Platform
- Speculation Heats Up Again In The Obesity Drug Space
- Celgene Moves Up After Upbeat Forecasts
- Venaxis Still Faces Challenges For Its APPY1 Test
- Peregrine Recovers As Phase II Trial Is Salvaged
- Ampio Stays Calm Ahead Of Further Developments
- Corcept Begins Recovery After Disastrous Launch Of Korlym
- Bears Target Accuray As Company Fails To Deliver
- Big Potential In Cancer Immunotherapy
- Weak Trading In Athersys Following Share Dilution
- Can AEterna Turn A New Leaf In 2013?
- 2 Impending Biotech Catalysts To Start Off 2013
- Amarin Trades Super Bearish Ahead Of Vascepa Launch
- The Market Awaits Financial Results From Nanosphere's Gram-Positive Test
- Investors Wait On Developments For Lexicon Pharmaceuticals
- Rockwell Heads Into 2013 With Major Catalysts
- Overvaluation In Pacira Pharmaceuticals Brings Shorting Opportunity
- Upcoming FDA Decision For AVEO's Tivozanib Builds Speculation
- Navidea: Unjustly Damaged By Misleading Article
- Rigel Recovers On 2013 Hope For Its Rheumatoid Arthritis Drug
- Ariad Sees Heavy Drop Following Spontaneous FDA Approval
- Cardiome Shares Remain Low On Merck's Abandonment